China Makes Example of GlaxoSmithKline in a Case That Involved Bribery of Doctors and Investigators and Ended With Guilty Pleas and Record Penalties

For more than a year, the drug maker brushed aside repeated warnings from a whistleblower about systemic fraud and corruption in its China operations. The case was fueled by missed clues, poor communication and a willful avoidance of the facts.

Click here to read article